三种预防方案对比他克莫司联合甲氨蝶呤预防移植物抗宿主病:一项随机2期试验
该研究纳入273例接受减低强度预处理造血干细胞移植的成人患者,随机分配至三种预防方案,并与224例接受他克莫司联合甲氨蝶呤的非随机对照比较。他克莫司+霉酚酸酯+移植后环磷酰胺组无GvHD无复发生存(GRFS)风险比0.72(90%CI 0.54-0.94;p=0.044),优于对照;他克莫司+甲氨蝶呤+硼替佐米组0.98(0.76-1.27;p=0.92)和他克莫司+甲氨蝶呤+马拉维若组1.10(0.86-1.41;p=0.49)与对照无显著差异。
要点
- 他克莫司+霉酚酸酯+移植后环磷酰胺组GRFS优于对照组,HR 0.72(90%CI 0.54-0.94;p=0.044)。
- 他克莫司+甲氨蝶呤+硼替佐米组和他克莫司+甲氨蝶呤+马拉维若组GRFS与对照无显著差异。
- 最常见毒性为血液学毒性和心脏毒性。
核心结论
- 他克莫司+霉酚酸酯+移植后环磷酰胺是最有前景的干预方案,GRFS最佳;该方案正在3期随机试验中与他克莫司联合甲氨蝶呤进行前瞻性比较。
研究设计与样本
- 前瞻性多中心2期试验,纳入18-75岁接受减低强度预处理造血干细胞移植的成人患者,随机分配(1:1:1)至三种预防方案,并与非随机同期对照(接受他克莫司+甲氨蝶呤)比较。
- 2014年11月17日至2016年5月18日,来自美国31个中心的273例患者随机分配:89例至他克莫司+甲氨蝶呤+硼替佐米组,92例至他克莫司+甲氨蝶呤+马拉维若组,92例至他克莫司+霉酚酸酯+移植后环磷酰胺组;6例被排除。
- 2014年8月1日至2016年9月14日,224例对照接受他克莫司+甲氨蝶呤。
- 主要终点为无GvHD无复发生存(GRFS),定义为从HCT至3-4级急性GvHD、需全身免疫抑制的慢性GvHD、疾病复发或死亡的时间。
- 分析采用改良意向性治疗。
主要发现
- 与对照相比,他克莫司+霉酚酸酯+移植后环磷酰胺组GRFS的风险比为0.72(90%CI 0.54-0.94;p=0.044)。
- 与对照相比,他克莫司+甲氨蝶呤+硼替佐米组GRFS的风险比为0.98(90%CI 0.76-1.27;p=0.92)。
- 与对照相比,他克莫司+甲氨蝶呤+马拉维若组GRFS的风险比为1.10(90%CI 0.86-1.41;p=0.49)。
- 238例患者发生3或4级毒性:他克莫司+霉酚酸酯+移植后环磷酰胺组12例(13%)发生3级事件、67例(73%)发生4级事件;他克莫司+甲氨蝶呤+硼替佐米组10例(11%)发生3级事件、68例(76%)发生4级事件;他克莫司+甲氨蝶呤+马拉维若组18例(20%)发生3级事件、63例(68%)发生4级事件。
- 最常见的毒性为血液学毒性(他克莫司+霉酚酸酯+移植后环磷酰胺组77例[84%]、他克莫司+甲氨蝶呤+硼替佐米组73例[82%]、他克莫司+甲氨蝶呤+马拉维若组78例[85%])和心脏毒性(分别为43例[47%]、44例[49%]、43例[47%])。
关键数值与推荐
- 他克莫司+霉酚酸酯+移植后环磷酰胺方案:环磷酰胺50 mg/kg,第3天和第4天;他克莫司从第5天开始,目标水平5-15 ng/mL;霉酚酸酯从第5天开始,15 mg/kg每日三次,不超过1 g,从第5天至第35天。
- 他克莫司+甲氨蝶呤+硼替佐米方案:硼替佐米1.3 mg/m2静脉注射,HCT后第1、4、7天。
- 他克莫司+甲氨蝶呤+马拉维若方案:马拉维若300 mg口服每日两次,从第-3天至HCT后第30天。
- 甲氨蝶呤给药:第1天15 mg/m2静脉推注,HCT后第3、6、11天10 mg/m2静脉推注;他克莫司静脉注射0.05 mg/kg每日两次(或等效口服),从第-3天开始(移植后环磷酰胺方案除外),目标水平5-15 ng/mL,至少持续至第90天,并在第180天前逐渐减停。
临床怎么用
- 原文结论认为他克莫司+霉酚酸酯+移植后环磷酰胺是最有前景的干预方案,GRFS最佳,该方案正在3期随机试验中与他克莫司联合甲氨蝶呤进行前瞻性比较。
局限性
- 对照为非随机同期队列,且对照组的合并症比干预组更频繁,预处理方案类型分布不同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prevention of graft-versus-host disease (GvHD) without malignant relapse is the overall goal of allogeneic haemopoietic cell transplantation (HCT). We aimed to evaluate regimens using either maraviroc, bortezomib, or post-transplantation cyclophosphamide for GvHD prophylaxis compared with controls receiving the combination of tacrolimus and methotrexate using a novel composite primary endpoint to identify the most promising intervention to be further tested in a phase 3 trial. METHODS: In this prospective multicentre phase 2 trial, adult patients aged 18-75 years who received reduced-intensity conditioning HCT were randomly assigned (1:1:1) by random block sizes to tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide (cyclophosphamide 50 mg/kg on days 3 and 4, followed by tacrolimus starting on day 5 and mycophenolate mofetil starting on day 5 at 15 mg/kg three times daily not to exceed 1 g from day 5 to day 35); tacrolimus, methotrexate, and bortezomib (bortezomib 1·3 mg/m2 intravenously on days 1, 4, and 7 after HCT); or tacrolimus, methotrexate, and maraviroc (maraviroc 300 mg orally twice daily from day -3 to day 30 after HCT). Methotrexate was administered as a 15 mg/m2 intravenous bolus on day 1 and 10 mg/m2 intravenous bolus on days 3, 6, and 11 after HCT; tacrolimus was given intravenously at a dose of 0·05 mg/kg twice daily (or oral equivalent) starting on day -3 (except the post-transplantation cyclophosphamide, as indicated), with a target level of 5-15 ng/mL. Tacrolimus was continued at least until day 90 and was tapered off by day 180. Each study group was compared separately to a contemporary non-randomised prospective cohort of patients (control group) who fulfilled the same eligibility criteria as the trial, but who were treated with tacrolimus and methotrexate at centres not participating in the trial. The primary endpoint (GvHD-free, relapse-free survival [GRFS]) was defined as the time from HCT to onset of grade 3-4 acute GvHD, chronic GvHD requiring systemic immunosuppression, disease relapse, or death. The study was analysed by modified intention to treat. The study is closed to accrual and this is the planned analysis. This trial is registered with ClinicalTrials.gov, number NCT02208037. FINDINGS: Between Nov 17, 2014, and May 18, 2016, 273 patients from 31 US centres were randomly assigned to the three study arms: 89 to tacrolimus, methotrexate, and bortezomib; 92 to tacrolimus, methotrexate, and maraviroc; 92 to tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; and six were excluded. Between Aug 1, 2014, and Sept 14, 2016, 224 controls received tacrolimus and methotrexate. Controls were generally well matched except for more frequent comorbidities than the intervention groups and a different distribution of types of conditioning regimens used. Compared with controls, the hazard ratio for GRFS was 0·72 (90% CI 0·54-0·94; p=0·044) for tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide, 0·98 (0·76-1·27; p=0·92) for tacrolimus, methotrexate, and bortezomib, and 1·10 (0·86-1·41; p=0·49) for tacrolimus, methotrexate, and maraviroc. 238 patients experienced grade 3 or 4 toxicities: 12 (13%) had grade 3 and 67 (73%) grade 4 events with tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; ten (11%) had grade 3 and 68 (76%) had grade 4 events with tacrolimus, methotrexate, and bortezomib; and 18 (20%) had grade 3 and 63 (68%) had grade 4 events with tacrolimus, methotrexate, and maraviroc. The most common toxicities were haematological (77 [84%] for tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; 73 [82%] for tacrolimus, methotrexate, and bortezomib; and 78 [85%] for tacrolimus, methotrexate, and maraviroc) and cardiac (43 [47%], 44 [49%], and 43 [47%], respectively). INTERPRETATION: Tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide was the most promising intervention, yielding the best GRFS; this regimen is thus being prospectively compared with tacrolimus and methotrexate in a phase 3 randomised trial. FUNDING: US National Health, Lung, and Blood Institute; National Cancer Institute; National Institute of Allergy and Infectious Disease; and Millennium Pharmaceuticals.
引用
- Bolaños-Meade J, Reshef R, Fraser R, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019. PMID: 30824040. doi:10.1016/S2352-3026(18)30221-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。